Please ensure Javascript is enabled for purposes of website accessibility

Why ImmunoGen, Inc. Stock Is on the Rise Today

By George Budwell - Apr 27, 2018 at 1:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ImmunoGen's lead product candidate appears to be on the right track.

What happened

Shares of the clinical-stage biotech ImmunoGen (IMGN -0.28%) rose by as much as 13.8% on heavy volume in early-morning trading today. The catalyst?

ImmunoGen's shares are heading higher in response to a positive interim data review for its experimental ovarian cancer drug, mirvetuximab soravtansine, or mirvetuximab for short. Specifically, the company said that an Independent Data Monitoring Committee recommended that the drug's late-stage trial in women with platinum-resistant ovarian cancer should continue without modification.

A doctor discussing a chart with a female cancer patient.

Image Source: Getty Images.

ImmunoGen's shares have cooled off somewhat since the opening bell, but they are still up by a healthy 9.51% as of 11:45 a.m. EDT Friday in response to this news. 

So what 

ImmunoGen has pegged mirvetuximab as its potential flagship product because of the enormous commercial opportunity proffered by ovarian cancer treatment. The company thinks that even as a later-line treatment for platinum-resistant ovarian cancer, for example, the drug could easily generate hundreds of millions in sales.

That being said, ImmunoGen also has its eye on expanding mirvetuximab into earlier lines of therapy as part of a combination treatment. And if this line of inquiry pans out, ImmunoGen could have a blockbuster on its hands. 

Now what

ImmunoGen expects this ongoing late-stage trial to produce top-line data sometime in the first half of 2019. So, if things go according to schedule, mirvetuximab should be on the market by early 2020.

While that's definitely encouraging news for shareholders, the downside is that the company will probably take advantage of this bump in its share price to raise capital soon. Although ImmunoGen did exit 2017 with a respectable $267 million in cash and cash equivalents, this amount simply isn't sufficient to support a commercial launch and advance the biotech's other clinical assets simultaneously, after all. In short, it might be wise to wait until the inevitable capital raise takes place before buying shares.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ImmunoGen, Inc. Stock Quote
ImmunoGen, Inc.
$3.57 (-0.28%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.